HCPCS J-Codes
Drugs administered other than oral method, chemotherapy drugs

These codes are used to report injectable drugs that ordinarily cannot be self-administered; chemotherapy, immunosuppressive drugs and inhalation solutions as well as some orally administered drugs.

View All HCPCS Sections

  • J9278

    Injection, carboplatin (avyxa), 1 mg

  • J9280

    Injection, mitomycin, 5 mg

  • J9281

    Mitomycin pyelocalyceal instillation, 1 mg

  • J9282

    Mitomycin, intravesical instillation, 1 mg

  • J9285

    Injection, olaratumab, 10 mg

  • J9286

    Injection, glofitamab-gxbm, 2.5 mg

  • J9289

    Injection, nivolumab, 2 mg and hyaluronidase-nvhy

  • J9292

    Injection, pemetrexed dipotassium, 10 mg

  • J9293

    Injection, mitoxantrone hydrochloride, per 5 mg

  • J9294

    Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg

  • J9295

    Injection, necitumumab, 1 mg

  • J9296

    Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg

  • J9297

    Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg

  • J9298

    Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg

  • J9299

    Injection, nivolumab, 1 mg

  • J9300

    Injection, gemtuzumab ozogamicin, 5 mg

  • J9301

    Injection, obinutuzumab, 10 mg

  • J9302

    Injection, ofatumumab, 10 mg

  • J9303

    Injection, panitumumab, 10 mg

  • J9304

    Injection, pemetrexed (pemfexy), 10 mg

  • J9305

    Injection, pemetrexed, not otherwise specified, 10 mg

  • J9306

    Injection, pertuzumab, 1 mg

  • J9307

    Injection, pralatrexate, 1 mg

  • J9308

    Injection, ramucirumab, 5 mg

  • J9309

    Injection, polatuzumab vedotin-piiq, 1 mg

  • J9310

    Injection, rituximab, 100 mg

  • J9311

    Injection, rituximab 10 mg and hyaluronidase

  • J9312

    Injection, rituximab, 10 mg

  • J9313

    Injection, moxetumomab pasudotox-tdfk, 0.01 mg

  • J9314

    Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg

  • J9315

    Injection, romidepsin, 1 mg

  • J9316

    Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg

  • J9317

    Injection, sacituzumab govitecan-hziy, 2.5 mg

  • J9318

    Injection, romidepsin, non-lyophilized, 0.1 mg

  • J9319

    Injection, romidepsin, lyophilized, 0.1 mg

  • J9320

    Injection, streptozocin, 1 gram

  • J9321

    Injection, epcoritamab-bysp, 0.16 mg

  • J9322

    Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg

  • J9323

    Injection, pemetrexed ditromethamine, 10 mg

  • J9324

    Injection, pemetrexed (pemrydi rtu), 10 mg

  • J9325

    Injection, talimogene laherparepvec, per 1 million plaque forming units

  • J9326

    Injection, telisotuzumab vedotin-tllv, 1 mg

  • J9328

    Injection, temozolomide, 1 mg

  • J9329

    Injection, tislelizumab-jsgr, 1mg

  • J9330

    Injection, temsirolimus, 1 mg

  • J9331

    Injection, sirolimus protein-bound particles, 1 mg

  • J9332

    Injection, efgartigimod alfa-fcab, 2mg

  • J9333

    Injection, rozanolixizumab-noli, 1 mg

  • J9334

    Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc

  • J9340

    Injection, thiotepa, 15 mg

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 7/22/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.